Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Mineralys Therapeutics will present new Phase 3 data from its Launch-HTN trial of lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The oral presentation, scheduled for May 30, 2026, will highlight the efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease (CKD).
Key figures
- Drug Name
- lorundrostat
- Phase Of Trial
- Phase 3
- Conference
- ESH 2026
- Trial name
- Launch-HTN
- Presentation date
- May 30, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.